This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): PHX1149, dutogliptin tartrate
Description: Dutogliptin is an orally-administered, once-daily selective inhibitor of DPP4, a serine protease. Inhibiting DPP4 increases the physiological levels of regulatory peptides, such as GLP-1, a modulator of insulin response and digestion.
Dutogliptin is renally excreted by passive filtration, not metabolized. It has no interactions with CYP450. Its half-life is 10 to 13 hours.
Deal Structure: Dutogliptin was originally developed by Phenomix.
Forest and Phenomix
In October 2008, Forest and Phenomix announced that they entered into a definitive collaboration agreement to develop and commercialize dutogliptin in North America.
Under the terms of the agreement, Forest will make an upfront payment to Phenomix of $75 million. Phenomix and Forest will jointly develop and commercialize dutogliptin in the United States, and the companies will equally share profits and expenses. Upon commercialization, the parties will co-promote the product in the United States, with Phenomix promoting dutogliptin to endocrinologists and diabetologists and Forest promoting to primary care and specialty physicians. Forest has exclusive rights to develop and commercialize dutogliptin in Canada and Mexico, and Phenomix will receive a royalty on sales in these countries in exchange for the rights to use jointly funded trial data in those countries. Phenomix retains development and...See full deal structure in Biomedtracker
Partners: Chiesi Farmaceutici S.p.A.
Additional information available to subscribers only: